Zoiray Technologies

Zoiray Technologies is successfully bootstrapping a high potential venture that promises prognostics to enable effective therapies for Alzheimer’s Disease.  Without a dime of venture capital or debt, Zoiray is shipping instruments and inking early access deals with researchers to develop content for its label-free multiplexed immunoassay platform.

The Competitive Advantage

Zoíray’s technology enables many immunoassays to be multiplexed on to one small disposable chip. While multiplexed immunoassays are emerging in life science research, existing techniques require a labeling step that adds significant variability, inhibits high density arrays, and provides a less quantifiable signal. Existing label-free detection technology is too costly and complex for many life science research labs let alone clinical use. With simple, inexpensive, label-free protein array detection, Zoíray expects to make a strong impact in molecular in vitro diagnostics with tests that provide far more information than is currently feasible.

The Market Strategy

Zoiray is targeting segments of the research market now and longer term, will break open and lead the professional POC market with a solution that helps detect Alzheimer’s Disease early.  The product platform appeals today to research users with an open platform that is far more simple and versatile than existing tools.  The breadth of Zoiray’s potential assay menu is large and rapidly increasing with the burgeoning discovery of new biomarkers.  This broad menu yields sustainable growth with new consumable products – as well as with strategic partnerships developing specific market segments through collaborative development and licensing.


Zoiray is actively engaged in and pursuing strategic partnerships with researchers, healthcare product companies, laboratory and clinical instrumentation companies, reagent suppliers, and pharmaceutical companies.  To date, Zoiray has planted seeds in the areas of liver disease, influenza, and Alzheimer’s disease – selling instruments, licensing software, and inking strategic “early access” and licensing agreements.

How did they do it?

In addition to sweat equity and long hours, SBIR NIH grants sparked disease-targeted application development.  Leveraging compelling early data, Zoiray successfully sold and shipped prototype instruments to influential thought leading researchers in these disease specific segments.  Zoiray focused its limited technical and marketing resources on seeding content development for its platform and on short term revenue.  It did not opt to focus on shopping business plans and pitching to venture capitalists – most of whom, today, are consumed with managing and funding vulnerable portfolio companies and are not making new early stage investments.  With each “early access” agreement, Zoiray receives cash, market intelligence, and content development for the platform.  And their valuation increases with each deal – enabling Zoirayto part with less equity in exchange for growth capital in an not-so-early stage investment.